WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`Recommended INN: List 54
`
`International Nonproprietary Names for
`Pharmaceutical Substances (INN)
`
`
`
`RECOMMENDED International Nonproprietary Names:
`List 54
`
`Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
`International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
`EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
`Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
`imply any recommendation of the use of the substance in medicine or pharmacy.
`Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in Cumulative List
`No. 11, 2004 (available in CD-ROM only).
`
`Dénominations communes internationales
`des Substances pharmaceutiques (DCI)
`
`Dénominations communes internationales RECOMMANDÉES:
`Liste 54
`
`Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
`Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
`Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies
`par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
`d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la
`substance correspondante en médecine ou en pharmacie.
`On trouvera d’autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans
`la Liste récapitulative No. 11, 2004 (disponible sur CD-ROM seulement).
`
`Denominaciones Comunes Internacionales
`para las Sustancias Farmacéuticas (DCI)
`
`Denominaciones Comunes Internacionales RECOMENDADAS:
`Lista 54
`
`De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
`Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
`EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
`continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
`inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
`alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
`Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran
`reunidas en Cumulative List No. 11, 2004 (disponible sólo en CD-ROM).
`
`
`
`243
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 001
`
`

`

`Recommended INN: List 54
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`Latin, English, French, Spanish:
`Recommended INN
`
`DCI Recommandée
`
`DCI Recomendada
`
`
`Chemical name or description; Molecular formula; Graphic formula
`
`Nom chimique ou description; Formule brute; Formule développée
`
`Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4-(4-chloro-2-hydroxybenzamido)butanoic acid
`
`acide 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoïque
`
`ácido 4-[(4-cloro-2-hidroxibenzoil)amino]butanoico
`
`C11H12ClNO4
`
`
`O
`
`CO2H
`
`
`
`NH
`
`OH
`
`Cl
`
`
`3-({4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-4'-methyl-
`[1,4'-bipiperidin]-1'-yl}carbonyl)-2,4-dimethylpyridine-1-oxide
`
`4-[(Z)-(4-bromophényl)(éthoxyimino)méthyl]-1'-[(2,4-diméthyl-
`1-oxydopyridin-3-yl)carbonyl]-4'-méthyl-1,4'-bipipéridinyle
`
`4-[(Z)-(4-bromofenil)(etoxiimino)metil]-1'-[(2,4-dimetil-1-oxidopiridin-
`3-il)carbonil]-4'-metil-1,4'-bipipéridinilo
`
`C28H37BrN4O3
`
`
`O
`
`CH3
`
`N
`
`O-
`N+
`
`CH3
`
`N
`
`N
`CH3
`
`CH3
`
`O
`
`Br
`
`
`
`
`(2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino=
`[2,3-e]indol-8-one
`
`(2S)-2-[(benzylamino)méthyl]-2,3,7,9-tétrahydro-8H-1,4-dioxino=
`[2,3-e]indol-8-one
`
`(2S)-2-[(bencilamino)metil]-2,3,7,9-tetrahidro-8H-1,4-dioxino=
`[2,3-e]indol-8-ona
`
`
`acidum salclobuzicum
`salclobuzic acid
`
`acide salclobuzique
`
`ácido salclobúzico
`
`
`
`
`
`ancrivirocum
`ancriviroc
`
`ancriviroc
`
`ancriviroc
`
`
`
`
`
`aplindorum
`aplindore
`
`aplindore
`
`aplindor
`
`
`
`244
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 002
`
`

`

`Recommended INN: List 54
`
`
`
`NH
`
`H
`
`OO
`
`C18H18N2O3
`
`
`O
`
`HN
`
`
`N-[(2S)-3-phenyl-2-(trimethylazaniumyl)propanoyl]-L-valyl-L-prolyl-
`L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-glutamyl-
`L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide
`
`N-[(2S)-3-phényl-2-(triméthylammonio)propanoyl]-L-valyl-L-prolyl-
`L-isoleucyl-L-phénylalanyl-L-thréonyl-L-tyrosylglycyl-L-glutamyl-
`L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide
`
`N-[(2S)-3-fenil-2-(trimetilamonio)propanoil]-L-valil-L-prolil-L-isoleucil-
`L-fenilalanil-L-treonil-L-tirosilglicil-L-glutamil-L-leucil-L-glutaminil-
`D-arginil-L-leucil-L-lisinamida
`
`C86H134N20O19
`
`
`O
`
`HN
`
`H
`
`Val Pro
`
`Ile Phe Thr Tyr Gly
`
`O
`
`CH3
`N+
`
`H
`
`H3C
`H3C
`
`Leu Gln D-Arg
`
`Leu Lys NH2
`
`-
`
`CO2
`
`
`
`
`4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-
`(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-
`5-carboxamide
`
`4-[(3-chloro-4-méthoxybenzyl)amino]-2-[(2S)-2-(hydroxyméthyl)=
`pyrrolidin-1-yl]-N-(pyrimidin-2-ylméthyl)pyrimidine-5-carboxamide
`
`4-[(3-cloro-4-metoxibencil)amino]-2-[(2S)-2-(hidroximetil)pirrolidin-
`1-il]-N-(pirimidin-2-ilmetil)pirimidina-5-carboxamida
`
`C23H26ClN7O3
`
`
`N
`
`245
`
`OH
`
`
`
`N
`
`H
`
`N
`
`N
`
`NH
`
`NH
`
`N
`
`O
`
`H3CO
`
`Cl
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`atilmotinum
`atilmotin
`
`atilmotine
`
`atilmotina
`
`
`
`
`
`avanafilum
`avanafil
`
`avanafil
`
`avanafilo
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 003
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`N-{1-[(cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propylpiperazin-
`1-yl)benzamide
`
`N-[1-[(cyanométhyl)carbamoyl]cyclohexyl]-4-(4-propylpipérazin-
`1-yl)benzamide
`
`N-[1-[(cianometil)carbamoil]ciclohexil]-4-(4-propilpiperazin-
`1-il)benzamida
`
`C23H33N5O2
`
`H3C
`
`N
`
`N
`
`
`
`NH
`
`O
`
`HN
`
`O
`
`N
`
`
`1,11-dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-
`β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo=
`[3,4-c]carbazole-5,7(6H)-dione
`
`1,11-dichloro-6-[2-(diéthylamino)éthyl]-12-(4-O-méthyl-
`β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo=
`[3,4-c]carbazole-5,7(6H)-dione
`
`1,11-dicloro-6-[2-(dietilamino)etil]-12-(4-O-metil-β-D-glucopiranosil)-
`12,13-dihidro-5H-indolo[2,3-a]pirrolo[3,4-c]carbazol-5,7(6H)-diona
`
`C33H34Cl2N4O7
`
`
`H3C
`
`N
`
`CH3
`
`O
`
`N
`
`O
`
`Cl
`
`N
`
`OH
`
`O
`
`NH
`
`OH
`
`Cl
`
`H3CO
`
`OH
`
`
`
`Recommended INN: List 54
`
`
`
`
`
`balicatibum
`balicatib
`
`balicatib
`
`balicatib
`
`
`
`
`
`becatecarinum
`becatecarin
`
`bécatécarine
`
`becatecarina
`
`
`
`
`
`
`
`
`
`
`
`
`
`246
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 004
`
`

`

`Recommended INN: List 54
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`
`(1R,3R)-4-(2-{(1R,3aS,7aR)-1-[(2S)-butan-2-yl]-7a-methyloctahydro-
`4H-inden-4-ylidene}ethylidene)-2-methylidenecyclohexane-1,3-diol
`
`(1R,3R)-2-méthylidène-5-[(2E)-2-[(1R,3aS,7aR)-7a-méthyl-
`1-[(1S)-1-méthylpropyl]octahydro-4H-indén-4-ylidène]éthylidène]=
`cyclohexane-1,3-diol
`
`(1R,3R)-2-metilideno-5-[(2E)-2-[(1R,3aS,7aR)-7a-metil-
`1-[(1S)-1-metilpropil]octahidro-4H-inden-4-ilideno]etilideno]=
`ciclohexano-1,3-diol
`
`C23H36O2
`
`
`H3C
`CH3
`
`H
`
`H
`
`CH3
`
`H
`
`HO
`
`H
`
`OH
`
`H
`
`CH2
`
`
`
`
`2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis=
`{5-[(2-ethylhexyl)oxy]phenol}
`
`2,2'-[6-(4-méthoxyphényl)-1,3,5-triazine-2,4-diyl]bis=
`[5-[(2-éthylhexyl)oxy]phénol]
`
`2,2'-[6-(4-metoxifenil)-1,3,5-triazina-2,4-diil]bis[5-[(2-etilhexil)=
`oxi]fenol]
`
`C38H49N3O5
`
`
`OCH3
`
`OH
`
`N
`
`N
`
`OH
`
`N
`
`H3C
`
`O
`
`H3C
`
`O
`
`CH3
`
`
`
`CH3
`
`247
`
`becocalcidiolum
`becocalcidiol
`
`bécocalcidiol
`
`becocalcidiol
`
`
`
`
`
`bemotrizinolum
`bemotrizinol
`
`bémotrizinol
`
`bemotrizinol
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 005
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`immunoglobulin G1, anti-(human CEA (carcinoembryonic
`antigen)-related antigen) (mouse monoclonal BW 250/183 heavy
`chain), disulfide with mouse monoclonal BW 250/183 κ-chain, dimer
`
`immunoglobuline G1, anti-(molécules de l’adhésion cellulaire,
`antigènes carcinoembryonaires humains (CEA ou CD66)), dimère du
`disulfure entre la chaîne lourde et la chaîne κ de l’anticorps
`monoclonal de souris BW 250/183
`
`inmunoglobulina G1, anti-(moléculas de adhesión celular, antígenos
`carcinoembrionarios humanos (CEA o CD66)), dímero del disulfuro
`entre la cadena pesada y la cadena κ del anticuerpo monoclonal de
`ratón BW 250/183
`
`
`
`2,2'-methylenebis[6-(2H-benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-
`2-yl)phenol]
`
`2,2'-méthylènebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-
`tétraméthylbutyl)phénol]
`
`2,2'-metilenobis[6-(2H-benzotriazol-2-il)-4-(1,1,3,3-tetrametilbutil)=
`fenol]
`
`C41H50N6O2
`
`
`OH
`
`OH
`
`N
`N
`
`N
`
`CH3
`
`H3C
`H3C
`
`CH3 H3C
`H3C
`CH3
`
`N
`N
`
`N
`
`CH3
`CH3
`CH3
`
`
`
`
`N-γ-L-glutaminyl-3-(2-{bis[bis(2-chloroethyl)amino]=
`phosphoryl}ethanesulfonyl)-L-alanyl-(2R)-2-phenylglycine
`
`acide (2S)-2-amino-5-[[(1R)-1-[[[2-[[bis[bis(2-chloroéthyl)amino]=
`phosphinoyl]oxy]éthyl]sulfonyl]méthyl]-2-[[(R)-carboxyphénylméthyl]=
`amino]-2-oxoéthyl]amino]-5-oxopentanoïque
`
`ácido (2S)-2-amino-5-[[(1R)-1-[[[2-[[bis[bis(2-cloroetil)amino]=
`fosfinoil]oxi]etil]sulfonil]metil]-2-[[(R)-carboxifenilmetil]amino]-
`2-oxoetil]amino]-5-oxopentanoico
`
`
`Recommended INN: List 54
`
`
`
`
`
`besilesomabum
`besilesomab
`
`bésilésomab
`
`besilesomab
`
`bisoctrizolum
`bisoctrizole
`
`bisoctrizole
`
`bisoctrizol
`
`
`
`
`
`canfosfamidum
`canfosfamide
`
`canfosfamide
`
`canfosfamida
`
`
`
`
`
`
`
`
`
`
`
`248
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 006
`
`

`

`Recommended INN: List 54
`
`
`
`N
`O P
`O
`
`N
`
`Cl
`
`Cl
`
`Cl
`
`CO2H
`
`HN
`
`O
`
`H
`
`C26H40Cl4N5O10PS
`
`
`Cl
`
`S
`
`O O
`
`H
`
`O
`
`NH
`
`HO2C
`
`H NH2
`
`
`(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=
`acetamido]-8-oxo-3-[(E){(3'R)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}=
`methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
`
`acide (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)=
`(hydroxyimino)acétyl]amino]-8-oxo-3-[(E)-[(3'R)-2-oxo-
`1,3'-bipyrrolidinyl-3-ylidène]méthyl]-5-thia-1-azabicyclo[4.2.0]oct-
`2-ène-2-carboxylique
`
`ácido (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=
`acetil]amino]-8-oxo-3-[(E)-[(3'R)-2-oxo-1,3'-bipirrolidinil-
`3-ilideno]metil]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico
`
`C20H22N8O6S2
`
`
`O
`
`N
`
`H
`
`NH
`
`
`
`CO2H
`
`N
`
`S
`
`H H
`
`O
`
`OH
`
`HN
`
`N
`
`N
`
`O
`
`N
`
`S
`
`H2N
`
`
`(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=
`acetamido]-3-[(E){(3'R)-1'-[(5-methyl-2-oxo-1,3-dioxol-4-yl)=
`methoxycarbonyl]-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}methyl]-8-oxo-
`5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
`
`acide (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)=
`(hydroxyimino)acétyl]amino]-3-[(E)-[(3'R)-1'-[[(5-méthyl-2-oxo-
`1,3-dioxol-4-yl)méthoxy]carbonyl]-2-oxo-1,3'-bipyrrolidinyl-
`3-ylidène]méthyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-
`2-carboxylique
`
`ácido (6R,7R)-7-[(2Z)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=
`acetamido]-3-[(E)-[(3'R)-1'-[[(5-metil-2-oxo-1,3-dioxol-
`4-il)metoxi]carbonil]-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-8-oxo-
`5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico
`
`
`249
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`ceftobiprolum
`ceftobiprole
`
`ceftobiprole
`
`ceftobiprol
`
`
`
`
`
`ceftobiprolum medocarilum
`ceftobiprole medocaril
`
`ceftobiprole médocaril
`
`ceftobiprol medocarilo
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 007
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`CH3
`
`O
`
`O
`
`O
`
`
`
`O O
`
`N
`
`O
`
`N
`
`H
`
`CO2H
`
`N
`
`S
`
`H H
`
`C26H26N8O11S2
`
`
`O
`
`OH
`
`HN
`
`N
`
`N
`
`O
`
`N
`
`S
`
`H2N
`
`
`toxin hIL13-PE38QQR (plasmid phuIL13-Tx)
`
`[Met17,His18]précurseur de l’interleukine-13 humaine-(17-132)-
`peptide (132→246')-protéine avec la
`dès-Ala365,Asp366,Val367,Val368,Ser369,Leu370,Thr371,Cys372,Pro373,Val374
`,Ala375,Ala376,Gly377,Glu378,Cys379,Ala380-
`[Lys246,Ala247,Ser248,Gly249,Gly250,Asn364,Val407,Ser515,Gln590,
`Gln606,Arg613]exotoxine A (Pseudomonas aeruginosa)-(246-613)-
`peptide
`
`toxina hIL13-PE38QQR (plásmido phuIL13-Tx)
`
`
`
`C2234H3512N650O682S10
`
`MHSPGPVPPS TALRELIEEL VNITQNQKAP LCNGSMVWSI
`NLTAGMYCAA LESLINVSGC SAIEKTQRML SGFCPHKVSA
`GQFSSLHVRD TKIEVAQFVK DLLLHLKKLF REGRFNKASG
`GPEGGSLAAL TAHQACHLPL ETFTRHRQPR GWEQLEQCGY
`PVQRLVALYL AARLSWNQVD QVIRNALASP GSGGDLGEAI
`REQPEQARLA LTLAAAESER FVRQGTGNDE AGAANGPADS
`GDALLERNYP TGAEFLGDGG DVSFSTRGTQ NWTVERLLQA
`HRQLEERGYV FVGYHGTFLE AAQSIVFGGV RARSQDLDAI
`WRGFYIAGDP ALAYGYAQDQ EPDARGRIRN GALLRVYVPR
`SSLPGFYRTS LTLAAPEAAG EVERLIGHPL PLRLDAITGP
`EEEGGRLETI LGWPLAERTV VIPSAIPTDP RNVGGDLDPS
`SIPDQEQAIS ALPDYASQPG QPPREDLR
`
`
`
`
`2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)=
`propyl]acetamide
`
`2-[4-(2-aminoéthoxy)-3-méthoxyphényl]-N-[3-(3,4-diméthylphényl)=
`propyl]acétamide
`
`2-[4-(2-aminoetoxi)-3-metoxifenil]-N-[3-(3,4-dimetilfenil)propil]=
`acetamida
`
`C22H30N2O3
`
`H3C
`
`OCH3
`
`O
`
`NH2
`
`O
`
`HN
`
`H3C
`
`Recommended INN: List 54
`
`
`
`
`
`
`
`cintredekinum besudotoxum
`cintredekin besudotox
`
`cintrédékine bésudotox
`
`
`
`cintredekina besudotox
`
`
`
`
`
`
`
`davasaicinum
`davasaicin
`
`davasaïcine
`
`davasaicina
`
`
`
`
`
`
`
`
`
`
`
`
`250
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 008
`
`

`

`Recommended INN: List 54
`
`
`(4S)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydro-1,3-thiazole-
`4-carboxylic acid
`
`acide (+)-(4S)-2-(2,4-dihydroxyphényl)-4-méthyl-4,5-dihydrothiazole-
`4-carboxylique
`
`ácido (+)-(4S)-2-(2,4-dihidroxifenil)-4-metil-4,5-dihidrotiazol-
`4-carboxílico
`
`C11H11NO4S
`
`
`H3C
`N
`
`CO2H
`
`S
`
`OH
`
`
`
`HO
`
`
`(2R)-2-[(2R)-2-{(2R)-2-[(2R)-2-{(2R)-2-[(2R)-2-(D-arginylamino)=
`hexanamido]hexanamido}hexanoyl-D-arginylamino]=
`hexanamido}hexanamido]hexanoylglycyl-D-tyrosinamide
`
`D-arginyl-(2R)-2-aminohexanoyl-(2R)-2-aminohexanoyl-
`(2R)-2-aminohexanoyl-D-arginyl-(2R)-2-aminohexanoyl-
`(2R)-2-aminohexanoyl-(2R)-2-aminohexanoylglycyl-D-tyrosinamide
`
`D-arginil-(2R)-2-aminohexanoil-(2R)-2-aminohexanoil-
`(2R)-2-aminohexanoil-D-arginil-(2R)-2-aminohexanoil-
`(2R)-2-aminohexanoil-(2R)-2-aminohexanoilglicil-D-tirosinamida
`
`C59H105N17O11
`
`
`HN
`
`HN
`
`251
`
`NH2
`
`NH2
`
`HN
`
`NH2
`
`O
`
`H
`
`HN
`
`O
`
`NH
`
`O
`
`HN
`
`O
`
`H
`
`HO
`
`NH
`
`H
`
`HN
`
`O
`
`HN
`
`H
`
`H2N
`
`CH3
`
`3
`
`CH3
`
`3
`
`OH
`
`
`2-methyl-1-{4-([2H3]methyl)[2,3,5,6-2H4]phenyl}-3-(piperidin-
`1-yl)propan-1-one
`
`(2RS)-2-méthyl-1-(4-(2H3)méthyl(2,3,5,6-2H4)phényl)-3-(pipéridin-
`1-yl)propan-1-one
`
`(2RS)-2-metil-1-(4-[2H3]metil[2,3,5,6-2H4]fenil)-3-(piperidin-
`1-il)propan-1-ona
`
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`deferitrinum
`deferitrin
`
`déféritrine
`
`deferitrina
`
`
`
`
`
`delmitidum
`delmitide
`
`delmitide
`
`delmitida
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`deutolperisonum
`deutolperisone
`
`deutolpérisone
`
`deutolperisona
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 009
`
`

`

`Recommended INN: List 54
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`efipladibum
`efipladib
`
`éfipladib
`
`efipladib
`
`
`
`
`
`elomotecanum
`elomotecan
`
`élomotécan
`
`elomotecán
`
`
`
`
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`C16H162H7NO
`
`
`N
`
`H3C
`
`O
`
`H
`2H
`
`2H
`
`2H
`
`2H
`
`C2H3
`
`and enantiomer
`et énantiomère
`y enantiómero
`
`
`
`
`4-(3-{5-chloro-2-[2-({[(3,4-dichlorophenyl)methyl]sulfonyl}amino)=
`ethyl]-1-(diphenylmethyl)-1H-indol-3-yl}propyl)benzoic acid
`
`acide 4-[3-[5-chloro-2-[2-[[(3,4-dichlorobenzyl)sulfonyl]amino]éthyl]-
`1-(diphénylméthyl)-1H-indol-3-yl]propyl]benzoïque
`
`ácido 4-[3-[5-cloro-2-[2-[[(3,4-diclorobencil)sulfonil]amino]etil]-
`1-(difenilmetil)-1H-indol-3-il]propil]benzoico
`
`C40H35Cl3N2O4S
`
`
`O
`O
`
`S
`NH
`
`N
`
`Cl
`
`Cl
`
`Cl
`CO2H
`
`
`
`
`(5R)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methylpiperidin-
`1-yl)methyl]-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]=
`indolizino[1,2-b]quinoline-3,15-dione
`
`(5R)-9-chloro-5-éthyl-5-hydroxy-10-méthyl-12-[(4-méthylpipéridin-
`1-yl)méthyl]-1,4,5,13-tétrahydro-3H,15H-oxépino[3’,4’:6,7]=
`indolizino[1,2-b]quinoléine-3,15-dione
`
`(5R)-9-cloro-5-etil-5-hidroxi-10-metil-12-[(4-metilpiperidin-1-il)metil]-
`1,4,5,13-tetrahidro-3H,15H-oxepino[3’,4’:6,7]indolizino=
`[1,2-b]quinolina-3,15-diona
`
`C29H32ClN3O4
`
`
`O
`
`H3C
`
`N
`
`N
`
`N
`
`HO
`
`H3C
`
`Cl
`
`O
`
`O
`
`CH3
`
`
`
`
`
`252
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0010
`
`

`

`Recommended INN: List 54
`
`
`4-{(1E,3E)-4-(trans-5-{[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-
`4-(1H-1,2,4-triazol-1-yl)butan-2-yl]sulfanyl}-1,3-dioxan-2-yl)buta-
`1,3-dien-1-yl}-3-fluorobenzonitrile
`
`(-)-4-[(1E,3E)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorophényl)-2-hydroxy-
`1-méthyl-3-(1H-1,2,4-triazol-1-yl)propyl]sulfanyl]-1,3-dioxan-
`2-yl]buta-1,3-diényl]-3-fluorobenzonitrile
`
`(-)-4-[(1E,3E)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorofenil)-2-hidroxi-
`1-metil-3-(1H-1,2,4-triazol-1-il)propil]sulfanil]-1,3-dioxan-2-il]buta-
`1,3-dienil]-3-fluorobenzonitrilo
`
`C27H25F3N4O3S
`
`
`F
`
`F
`HO
`
`H CH3
`
`N
`
`N
`
`N
`
`
`
`S
`H
`
`O O
`
`H
`
`F
`
`NC
`
`
`1-165-erythropoietin (human clone B03XA01), glycoform ζ
`
`1-165-érythropoïétine (humaine B03XA01), glycoforme ζ
`
`1-165-eritropoyetina (humana B03XA01), glicoforma ζ
`
`C809H1301N229O240S5
`
`
`
`2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-(octadec-
`11-enamido)-4-O-phosphono-β-D-glucopyranosyl-(1→6)-3-O-decyl-
`2-deoxy-2-(3-oxotetradecanamido)-α-D-glucopyranose
`1-(dihydrogen phosphate)
`
`dihydrogénophosphate de 3-O-décyl-2-désoxy-6-O-[2-désoxy-
`3-O-[(3R)-3-méthoxydécyl]-6-O-méthyl-2-[(11Z)-octadéc-
`11-énoylamino]-4-O-phosphono-β-D-glucopyranosyl]-
`2-[(3-oxotétradécanoyl)amino]-α-D-glucopyranosyle
`
`dihidrógenofosfato de 3-O-decil-2-desoxi-6-O-[2-desoxi-3-O-[(3R)-3-
`metoxidecil]-6-O-metil-2-[(11Z)-octadec-11-enamido]-4-O-fosfono-
`β-D-glucopiranosil]-2-(3-oxotetradecanamido)-α-D-glucopiranosilo
`
`
`253
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`embeconazolum
`embeconazole
`
`embéconazole
`
`embeconazol
`
`
`
`
`
`epoetinum zeta
`epoetin zeta
`
`époétine zêta
`
`epoetina zeta
`
`
`
`eritoranum
`eritoran
`
`éritoran
`
`eritorán
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0011
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`C66H126N2O19P2
`
`
`H3C
`
`H3C
`
`H3CO
`OCH3
`
`H
`
`O
`
`O
`
`O
`
`H2O3P
`
`CH3
`
`O
`
`O
`
`NH
`HO
`
`O
`
`O
`
`O
`
`O
`
`O
`NH
`
`PO3H2
`
`CH3
`
`
`
`
`2-(3-{3-[(5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy]propoxy}-
`2-propylphenoxy)benzoic acid
`
`acide 2-[3-[3-[(5-éthyl-4'-fluoro-2-hydroxybiphényl-4-yl)oxy]propoxy]-
`2-propylphénoxy]benzoïque
`
`ácido 2-[3-[3-[(5-etil-4'-fluoro-2-hidroxibifenil-4-il)oxi]propoxi]-
`2-propilfenoxi]benzoico
`
`C33H33FO6
`
`F
`
`OH
`
`O
`
`CH3
`
`O
`H3C
`
`O
`
`CO2H
`
`
`
`
`5-[(piperidin-1-yl)carbonyl]-2,1,3-benzooxadiazole
`
`1-(2,1,3-benzoxadiazol-5-ylcarbonyl)pipéridine
`
`1-(2,1,3-benzoxadiazol-5-ilcarbonil)piperidina
`
`C12H13N3O2
`
`
`O
`
`O
`
`N
`
`N
`
`N
`
`
`
`
`7-(5-amino-1,5-dideoxy-β-D-ribofuranos-1-yl)-1,5-dihydro-
`4H-pyrrolo[3,2-d]pyrimidin-4-one
`
`(-)-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyméthyl)pyrrolidin-2-yl]-
`1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
`
`(-)-7-[(2S,3S,4R,5R)-3,4-dihidroxi-5-(hidroximetil)pirrolidin-2-il]-
`1,5-dihidro-4H-pirrolo[3,2-d]pirimidin-4-ona
`
`
`Recommended INN: List 54
`
`
`
`
`
`
`
`etalocibum
`etalocib
`
`étalocib
`
`etalocib
`
`
`
`
`
`farampatorum
`farampator
`
`farampator
`
`farampator
`
`
`
`
`
`forodesinum
`forodesine
`
`forodésine
`
`forodesina
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`254
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0012
`
`

`

`Recommended INN: List 54
`
`HN
`
`C11H14N4O4
`
`
`O
`
`NH
`
`HN
`
`N
`
`HO
`
`OH
`
`OH
`
`
`
`
`N-acetylgalactosamine 4-sulfatase (human CSL4S-342 cell)
`
`N-acétylgalactosamine 4-sulfatase (cellule humaine CSL4S-342)
`
`N-acetilgalactosamina 4-sulfatasa (célula humana CSL4S-342)
`
`C2529H3843N689O716S16
`
`AGASRPPHLV
`FLLADDLGWN
`GVLLDNYYTQ
`PLCTPSRSQL
`PSCVPLDEKL
`LPQLLKEAGY
`RRGFDTYFGY
`LLGSEDYYSH
`GEEVATGYKN
`MYSTNIFTKR
`QSVHEPLQVP
`EEYLKPYDFI
`NVTAALKSSG
`LWNNTVFIFS
`WSLWEGGVRG
`VGFVASPLLK
`KLARGHTNGT
`KPLDGFDVWK
`FVDSSPCPRN
`SMAPAKDDSS
`KLLTGYPGCG
`YWFPPPSQYN
`RDPEERHDLS
`REYPHIVTKL
`PRCDPKATGV
`WGPWM
`
`DVGFHGSRIR
`LTGRYQIRTG
`TTHMVGKWHL
`ERCTLIDALN
`AIALITNHPP
`QDKNRHHYAG
`TDNGGQTLAG
`QKGVKNRELI
`TISEGSPSPR
`LPEYSAFNTS
`VSEIPSSDPP
`LSRLQFYHKH
`
`TPHLDALAAG
`LQHQIIWPCQ
`GMYRKECLPT
`VTRCALDFRD
`EKPLFLYLAL
`MVSLMDEAVG
`GNNWPLRGRK
`HISDWLPTLV
`IELLHNIDPN
`VHAAIRHGNW
`TKTLWLFDID
`SVPVYFPAQD
`
`glucarpidasum
`glucarpidase
`
`glucarpidase
`
`glucarpidasa
`
`
`recombinant glutamate carboxypeptidase (carboxypeptidase G2)
`
`[405-arginine]précurseur de la carboxypeptidase G2 de
`Pseudomonas (RS-16), enzyme à zinc dimérique, glutamate
`carboxypeptidase
`
`glutamato carboxipeptidasa recombinante (carboxipeptidasa G2)
`
`
`
`
`255
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`galsulfasum
`galsulfase
`
`galsulfase
`
`galsulfasa
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0013
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`C1950H3157N543O599S7 (monomer)
`
`GTALAQKRDN
`MRPSIHRTAI
`AAVLATAFVA
`VLFQAATDEQ
`EGIAAAGNFL
`PAVIKTLEKL
`VNIETGTGDA
`EAELKNLGFT
`GRGGKNLLLM
`VTRSKSAGLV
`VGDNIVGKIK
`SHMDTVYLKG
`DDKGGNAVIL
`GDKAYGPGIA
`ILAKAPFRVE
`HTLKLLKEYG
`GSRDLIQEEA
`VRDYGTITVL
`FNTDEEKGSF
`KLADYVLSFE
`PTSAGDEKLS
`LGTSGIAYVQ VNITGKASHA GAAPELGVNA
`LVEASDLVLR TMNIDDKAKN LRFNWTIAKA
`GNVSNIIPAS
`LPEADVKVIV
`ATLNADVRYA
`RNEDFDAAMK
`TLEERAQQKK
`EGGKKLVDKA
`VAYYKEAGGT
`LGVEERTGGG
`TRGRPAFNAG
`GFGYHSDKAE
`YVDISAIPRR
`TDAAYAALSG
`KPVIESLGLP
`LYMARRLIMD
`LGAGK
`
`
`a recombinant human interleukin-18 with 157 amino acids
`
`interleukine-18 humaine recombinante (157 aminoacides)
`
`interleukina-18 humana recombinante (157 aminoácidos)
`
`C801H1264N212O252S10
`
`YFGKLESKLS
`VIRNLNDQVL
`NAPRTIFIIS
`MYKDSQPRGM
`ISFKEMNPPD
`NIKDTKSDII
`EGYFLACEKE
`RDLFKLILKK
`
`FIDQGNRPLF
`AVTISVKCEK
`FFQRSVPGHD
`EDELGDRSIM
`
`EDMTDSDCRD
`ISTLSCENKI
`NKMQFESSSY
`FTVQNED
`
`
`
`
`(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
`
`acide (5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tétraénoïque
`
`ácido (5Z,8Z,11Z,13E,15S)-15-hidroxiicosa-5,8,11,13-tetraenoico
`
`C20H32O3
`
`
`CO2H
`
`H3C
`
`H
`OH
`
`
`
`Recommended INN: List 54
`
`
`
`
`
`
`
`
`
`iboctadekinum
`iboctadekin
`
`iboctadékine
`
`iboctadekina
`
`
`
`
`
`icomucretum
`icomucret
`
`icomucret
`
`icomucret
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`256
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0014
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`Recommended INN: List 54
`
`
`immunoglobulin G4, anti-(human CD22 (antigen)) (human-mouse
`monoclonal G544 heavy chain), disulfide with human-mouse
`monoclonal G544 κ-chain, dimer, conjugate with methyl
`N-{(1R,4Z,8S,13E)-8-(4,6-dideoxy-4-{[(4-S-{4-[(6-deoxy-3-O-methyl-
`α-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl}-
`4-thio-β-D-ribo-hexopyranosyl)oxy]amino}-2-O-[4-(N-
`ethylacetamido)-2,4-dideoxy-3-O-methyl-α-L-threo-pentopyranosyl]-
`β-D-glucopyranosyloxy)-13-[2-({4-[2-(1-{[4-(4-amino-
`4-oxobutyl)oxy]phenyl}ethylidene)hydrazinyl]-2-methyl-4-oxobutan-
`2-yl}disulfanyl)ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-
`4,9-diene-2,6-diyn-10-yl}carbamate
`
`N-[4-[4-[1-[[3-[[2-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acétyléthylamino)-
`2,4-didésoxy-3-O-méthyl-α-L-thréo-pentopyranosyl]-4,6-didésoxy-
`4-[[[2,6-didésoxy-4-S-[4-[(6-désoxy-3-O-méthyl-
`α-L-mannopyranosyl)oxy]-3-iodo-5,6-diméthoxy-2-méthylbenzoyl]-
`4-thio-β-D-ribo-hexopyranosyl]oxy]amino]-β-D-glucopyranosyl]oxy]-
`1-hydroxy-10-[(méthoxycarbonyl)amino]-11-oxobicyclo[7.3.1]tridéca-
`4,9-diène-2,6-diyn-13-ylidène]éthyl]disulfanyl]-3-méthylbutanoyl]=
`diazanylidène]éthyl]phénoxy]butanoyl]immunoglobuline G4,
`anti-(antigène CD22 humain) dimère du disulfure entre la chaîne
`lourde et la chaîne κ de l'anticorps monoclonal de souris G544
`humanisé
`
`N-[4-[4-[1-[[3-[[2-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acetiletilamino)-
`2,4-didesoxi-3-O-metil-α-L-treo-pentopiranosil]-4,6-didesoxi-
`4-[[[2,6-didesoxi-4-S-[4-[(6-desoxi-3-O-metil-α-L-manopiranosil)oxi]-
`3-iodo-5,6-dimetoxi-2-metilbenzoil]-4-tio-β-D-ribo-hexopiranosil]=
`oxi]amino]-β-D-glucopiranosil]oxi]-1-hidroxi-10-[(metoxicarbonil)=
`amino]-11-oxobiciclo[7.3.1]trideca-4,9-dieno-2,6-diino-
`13-ilideno]etil]disulfanil]-3-metilbutanoil]diazanilideno]etil]fenoxi]=
`butanoil]inmunoglobulina G4, anti-(antigeno CD22 humano) dimero
`del disulfuro entre la cadena pesada y la cadena κ del anticuerpo
`monoclonal humanizado de ratón G544
`
`
`
`C6518H10002N1738O2036S42
`
`
`Ig-NH2 = inotuzumab
`
`OCH3 O
`
`H3C
`
`O
`
`O
`CH3
`
`OH
`
`O O
`
`NH
`
`CH3
`
`S S
`
`OH
`
`O NH
`
`O O
`
`H
`
`H3C
`H3C
`O
`
`HN
`
`N
`
`CH3
`
`H3CO
`
`HO
`
`O O
`
`CH3
`
`I
`
`H3CO
`
`OH
`
`S
`
`CH3
`
`OH
`H3C
`
`O
`
`CH3
`
`O
`
`N
`
`O
`
`
`
`257
`
`O
`
`OCH3
`
`O
`
`NH
`
`Ig
`
`inotuzumabum ozogamicinum
`inotuzumab ozogamicin
`
`inotuzumab ozogamicine
`
`inotuzumab ozogamicina
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0015
`
`

`

`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`3-{(1RS,2RS)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenyl
`2-hydroxybenzoate
`
`2-hydroxybenzoate de 3-[(1RS,2RS)-2-[(diméthylamino)méthyl]-
`1-hydroxycyclohexyl]phényle
`
`2-hidroxibenzoato de 3-[(1RS,2RS)-2-[(dimetilamino)metil]-
`1-hidroxiciclohexil]fenilo
`
`C22H27NO4
`
`
`H3
`
`NC
`
`H
`
`HO
`
`O
`
`OH
`
`O
`
`CH3
`
`and enantiomer
`et énantiomère
`y enantiómero
`
`
`
`
`N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-
`3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
`
`N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-
`3,4-dihydroquinazolin-2-yl)-2-méthylpropyl]-4-méthylbenzamide
`
`N-(3-aminopropil)-N-[(1R)-1-(3-bencil-7-cloro-4-oxo-
`3,4-dihidroquinazolin-2-il)-2-metilpropil]-4-metilbenzamida
`
`C30H33ClN4O2
`
`
`O
`
`CH3
`H
`
`N
`
`N
`
`NH2
`
`Cl
`
`
`
`OH
`
`3C
`
`N
`
`H3C
`
`
`(5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-
`5H-2,3-benzodiaxepine
`
`(-)-(5S)-1-(3,4-diméthoxyphényl)-5-éthyl-7,8-diméthoxy-4-méthyl-
`5H-2,3-benzodiazépine
`
`(-)-(5S)-1-(3,4-dimetoxifenil)-5-etil-7,8-dimetoxi-4-metil-
`5H-2,3-benzodiazepina
`
`
`Recommended INN: List 54
`
`isalmadolum
`isalmadol
`
`isalmadol
`
`isalmadol
`
`
`
`
`
`
`
`
`
`ispinesibum
`ispinesib
`
`ispinésib
`
`ispinesib
`
`
`
`
`
`levotofisopamum
`levotofisopam
`
`lévotofisopam
`
`levotofisopam
`
`
`
`
`
`
`
`
`
`
`
`258
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0016
`
`

`

`Recommended INN: List 54
`
`NC
`
`H3
`
`N
`
`CH3
`H
`
`C22H26N2O4
`
`
`H3CO
`
`H3CO
`
`H3CO
`
`OCH3
`
`
`
`
`8-{[(2,6-dimethylphenyl)methyl]amino}-N-(2-hydroxyethyl)-
`2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
`
`8-[(2,6-diméthylbenzyl)amino]-N-(2-hydroxyéthyl)-
`2,3-diméthylimidazo[1,2-a]pyridine-6-carboxamide
`
`8-[(2,6-dimetilbencil)amino]-N-(2-hidroxietil)-2,3-dimetilimidazo=
`[1,2-a]piridina-6-carboxamida
`
`C21H26N4O2
`
`
`CH3
`
`CH3
`
`OH
`
`
`
`N
`
`NH
`
`N
`
`CH3
`
`HN
`
`CH3
`
`O
`
`
`3-hydroxy-17-methyl-4,5α-epoxymorphin-7-en-6α-yl
`β-D-glucopyranosiduronic acid
`
`acide β-D-glucopyranosiduronique de 7,8-didéshydro-4,5α-époxy-
`3-hydroxy-17-méthylmorphinan-6α-yle
`
`ácido β-D-glucopiranosidurónico de 7,8-dideshidro-4,5α-epoxi-
`3-hidroxi-17-metilmorfinan-6α-ilo
`
`C23H27NO9
`
`
`CH3
`
`H
`
`O
`
`N
`
`HH
`
`O H
`CO2H
`O
`
`OH
`
`HO
`
`HO
`
`OH
`
`
`
`259
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`
`
`
`linaprazanum
`linaprazan
`
`linaprazan
`
`linaprazán
`
`
`
`
`
`morphini glucuronidum
`morphine glucuronide
`
`glucuronide de morphine
`
`glucurónido de morfina
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0017
`
`

`

`Recommended INN: List 54
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`
`(2S)-2-methoxy-3-{4-[3-(4-phenoxyphenoxy)propoxy]phenyl}=
`propanoic acid
`
`acide (2S)-2-méthoxy-3-[4-[3-(4-phénoxyphénoxy)propoxy]phényl]=
`propanoïque
`
`ácido (2S)-2-metoxi-3-[4-[3-(4-fenoxifenoxi)propoxi]fenil]propanoico
`
`C25H26O6
`
`
`O
`
`O
`
`H
`
`OCH3
`
`CO2H
`
`
`
`O
`
`
`2-{(1E,3E,5E)-7-[(2E)-3,3-dimethyl-5-sulfonato-1-(2-sulfonatoethyl)-
`1,3-dihydro-2H-indol-2-ylidene]-4-methylhepta-1,3,5-trienyl}-
`3,3-dimethyl-1-(2-sulfonatoethyl)-3H-indolium-5-sulfonate
`
`trihydrogéno-2-[(1E,3E,5E)-7-[(2E)-3,3-diméthyl-5-sulfonato-
`1-(2-sulfonatoéthyl)-1,3-dihydro-2H-indol-2-ylidène]-4-méthylhepta-
`1,3,5-triényl]-3,3-diméthyl-1-(2-sulfonatoéthyl)-3H-indolium-
`5-sulfonate
`
`trihidrógeno-2-[(1E,3E,5E)-7-[(2E)-3,3-dimetil-5-sulfonato-
`1-(2-sulfonatoetil)-1,3-dihidro-2H-indol-2-ilideno]-4-metilhepta-
`1,3,5-trienil]-3,3-dimetil-1-(2-sulfonatoetil)-3H-indolio-5-sulfonato
`
`C32H38N2O12S4
`
`
`-O3S
`
`N+
`
`-
`
`SO3
`
`N
`
`3 H+
`
`-O3S
`
`CH3
`CH3
`
`CH3
`
`H3C
`H3C
`
`-
`
`SO3
`
`
`
`
`N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-{4-[2-(5-methyl-2-phenyl-
`1,3-oxazol-4-yl)ethoxy]phenyl}ethyl]glycine
`
`acide [[(4-méthoxyphénoxy)carbonyl][(1S)-1-[4-[2-(5-méthyl-
`2-phényloxazol-4-yl)éthoxy]phényl]éthyl]amino]acétique
`
`ácido [[(4-metoxifenoxi)carbonil][(1S)-1-[4-[2-(5-metil-2-feniloxazol-
`4-il)etoxi]fenil]etil]amino]acético
`
`C30H30N2O7
`
`
`CO2H
`
`N
`
`O
`
`H CH3
`
`O
`
`OCH3
`
`
`
`O
`
`CH3
`
`N O
`
`naveglitazarum
`naveglitazar
`
`navéglitazar
`
`naveglitazar
`
`
`
`
`
`omocianinum
`omocianine
`
`omocianine
`
`omocianina
`
`
`
`
`
`peliglitazarum
`peliglitazar
`
`péliglitazar
`
`peliglitazar
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`260
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0018
`
`

`

`Recommended INN: List 54
`
`
`(2S)-4-[(2-methylphenyl)sulfanyl]-2-[4-(trifluromethyl)phenoxy]=
`butanoic acid
`
`(-)-acide (2S)-4-[(2-méthylphényl)sulfanyl]-2-[4-(trifluorométhyl)=
`phénoxy]butanoïque
`
`(-)-ácido (2S)-4-[(2-metilfenil)sulfanil]-2-[4-(trifluorometil)fenoxi]=
`butanoico
`
`C18H17F3O3S
`
`F3C
`
`H3C
`CO2H
`
`H
`
`O
`
`S
`
`
`
`
`1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane
`
`1,1,1,2,3,3,3-heptafluoro-2-(trifluorométhyl)propane
`
`1,1,1,2,3,3,3-heptafluoro-2-(trifluorometil)propano
`
`C4F10
`
`
`F
`
`CF3
`
`F3C
`
`CF3
`
`
`
`
`3-chloro-4-[4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-1'-yl)butyl]-
`1,4-benzoxazepin-5(4H)-one
`
`3-chloro-4-[4-(3',6'-dihydro-2,4'-bipyridinyl-1'(2'H)-yl)butyl]-
`1,4-benzoxazépin-5(4H)-one
`
`3-cloro-4-[4-(3',6'-dihidro-2,4'-bipiridinil-1'(2'H)-il)butil]-
`1,4-benzoxazepin-5(4H)-ona
`
`C23H24ClN3O2
`
`
`Cl
`
`O
`
`N
`
`O
`
`N
`
`N
`
`
`
`261
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`pemaglitazarum
`pemaglitazar
`
`pémaglitazar
`
`pemaglitazar
`
`
`
`
`
`perflisobutanum
`perflisobutane
`
`perflisobutane
`
`perflisobutano
`
`
`
`
`
`piclozotanum
`piclozotan
`
`piclozotan
`
`piclozotán
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0019
`
`

`

`Recommended INN: List 54
`
`WHO Drug Information, Vol. 19, No. 3, 2005
`
`pralatrexatum
`pralatrexate
`
`pralatrexate
`
`pralatrexato
`
`
`
`
`
`radoterminum
`radotermin
`
`radotermine
`
`radotermina
`
`
`
`
`
`raxibacumabum
`raxibacumab
`
`raxibacumab
`
`raxibacumab
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`262
`
`
`N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic
`acid
`
`acide (2S)-2-[[4-[(1RS)-1-[(2,4-diaminoptéridin-6-yl)méthyl]but-
`3-ynyl]benzoyl]amino]pentanedioïque
`
`ácido (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-il)metil]but-
`3-inil]benzoil]amino]pentanodioico
`
`C23H23N7O5
`
`
`H
`
`CO2H
`
`and epimer at C*
`et l'épimère en C*
`y el epímero en C*
`
`CO2H
`
`NH
`
`O
`
`*
`
`H
`
`CH
`
`NN
`
`NH2
`
`N
`
`H2N
`
`N
`
`
`
`2
`
`
`growth differentiation factor 5 (human), homodimer
`
`facteur 5 humain de différenciation de la croissance, homodimère
`produit par E. coli
`
`factor 5 humano de diferenciación del crecimiento homodímero
`producido por E. coli
`
`C1184H1844N330O350S22
`
`
`PLATRQGKRP SKNLKARCSR KALHVNFKDM
`EYEAFHCEGL CEFPLRSHLE PTNHAVIQTL
`PTCCVPTRLS PISILFIDSA NNVVYKQYED
`
`GWDDWIIAPL
`MNSMDPESTP
`MVVESCGCR
`
`
`immunoglobulin G1, anti-(anthrax protective antigen) (human
`monoclonal PA heavy chain), disulfide with human monoclonal PA
`λ-chain, dimer
`
`immunoglobuline G1, anti-(antigen protecteur de l'anthrax), dimère
`du disulfure entre la chaine lourde et la chaîne λ de l'anticorps
`monoclonal humain PA
`
`inmunoglobulina G1, anti-(antígeno protector del antrax), dímero del
`disulfuro entre la cadena pesada y la cadena λ del anticuerpo
`monoclonal humano PA
`
`C6320H9794N1702O1998S42
`
`
`Breckenridge Exhibit 1078
`Temsirolimus INN
`Page 0020
`
`

`

`Recommended INN: List 54
`
`
`N-(aminoiminomethyl)-4,5-bis(methanesulfonyl)-2-methylbenzamide
`
`N-carbamimidoyl-2-méthyl-4,5-bis(méthylsulfonyl)benzamide
`
`N-carbamimidoil-2-metil-4,5-bis(metilsulfonil)benzamida
`
`C11H15N3O5S2
`
`
`O
`
`NH
`
`NH2
`
`
`
`NH
`
`CH3
`
`H3C
`H3C
`
`OO
`S
`
`S
`O O
`
`
`(1S,3S,5S)-2-{(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl}-
`2-azabicyclo[3.1.0]hexane-3-carbonitrile
`
`(1S,3S,5S)-2-[(2S)-amino(3-hydroxytricyclo[3.3.1.13,7]déc-1-yl)=
`acétyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
`
`(1S,3S,5S)-2-[(2S)-amino(3-hidroxitriciclo[3.3.1.13,7]dec-1-il)acetil]-
`2-azabiciclo[3.1.0]hexano-3-carbonitrilo
`
`C18H25N3O2
`
`
`O
`
`H2N
`
`N
`
`H
`H
`
`OH
`
`H
`
`CN
`
`H
`
`
`
`
`(2R)-2-{[6-benzylamino-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-
`1-ol
`
`(-)-(2R)-2-[[6-(benzylamino)-9-(1-méthyléthyl)-9H-purin-2-yl]amino]=
`butan-1-ol
`
`(-)-(2R)-2-[[6-(bencilamino)-9-(1-metiletil